OS Therapies closes $6M private placement; funds operations into 2026

OS Therapies Inc

Raised $6.05M gross from sale of 1,512,500 units at $4.00/unit; each unit has Series A Convertible Preferred share and a warrant.
Conversion price of preferred is $4.00; warrant exercise price is $4.40 per share.
Cash runway expected into 2026; 98% of investment from pre-IPO or IPO investors.
Data update from OST-HER2 Phase 2b trial in osteosarcoma to be announced during JP Morgan Healthcare Conference week.
Company entered waiver with ELOC investor Square Gate Capital, including cash payments and issuance of additional shares.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.